Shai Magidi
A5053625131- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics, Bioinformatics, and Biomedical Research
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- COVID-19 Clinical Research Studies
- BRCA gene mutations in cancer
- Bioinformatics and Genomic Networks
- Cancer, Stress, Anesthesia, and Immune Response
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
WIN Consortium
2021-2024
Worldwide Universities Network
2021-2023
The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tissue biopsies. SPRING is first trial assess a SIMS-based tri-therapy regimen in advanced non-small cell lung (NSCLC).Patients with NSCLC (no EGFR, ALK, or ROS1 alterations; PD-L1 unrestricted; ≤2 prior therapy lines) received avelumab, axitinib, palbociclib (3 + 3 dose...
Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate patient enrollment early phase trials and failure drugs III studies. Objective: Integrating transcriptomics for selection patients has the potential achieve enhanced speed efficacy precision any targeted therapies or immunotherapies. Methods: Relative gene expression level metastasis normal organ-matched tissues from WINTHER database was used estimate silico benefit...
// Wafik S. El-Deiry 1 , 2 Catherine Bresson Fanny Wunder Benedito A. Carneiro Don Dizon Jeremy L. Warner Stephanie Graff Christopher G. Azzoli Eric T. Wong Liang Cheng Sendurai Mani Howard P. Safran Casey Williams 3 Tobias Meissner Benjamin Solomon Eitan Rubin 4 Angel Porgador Guy Berchem 5 6 7 Pierre Saintigny 8 9 Amir Onn 10 Jair Bar 11 Raanan Berger Manon Gantenbein Zhen Chen 12 Cristiano de Pádua Souza 13 Rui Manuel Vieira Reis 14 Marina Sekacheva 15 Andrés Cervantes 16 William Dahut 17...
Abstract The expanding targeted therapy landscape requires combinatorial biomarkers for patient stratification and treatment selection. This simultaneous exploration of multiple genes relevant networks to account the complexity mechanisms that govern drug sensitivity predict clinical outcomes. We present algorithm, Digital Display Precision Predictor (DDPP), aiming identify transcriptomic predictors outcome. For example, 17 13 key were derived from literature by their association with MTOR...
Background: Dysregulated pathways in cancer may be hub addicted. Identifying these dysregulated networks for targeting might lead to novel therapeutic options. Objective: Considering the hypothesis that central hubs are associated with increased lethality, identifying key targets within could development of drugs improved efficacy advanced metastatic solid tumors. Design: Exploring transcriptomic data (22,000 gene products) from WINTHER trial ( N = 101 patients various cancers), which both...
SARS-CoV-2 (COVID-19) elicits a T-cell antigen-mediated immune response of variable efficacy. To understand this variability, we explored transcriptomic expression angiotensin-converting enzyme 2 (ACE2, the receptor) and immunoregulatory genes in normal lung tissues from patients with non-small cell cancer (NSCLC).This study used clinical data for NSCLC generated during CHEMORES [n = 123 primary resected (early-stage) NSCLC] WINTHER trial (n 32 metastatic NSCLC).We identified patient...
PURPOSE The prognosis of patients with non–small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features tumor that may be important in determining patient outcome guiding therapeutic interventions. Identifying NSCLC at increased risk recurrence after curative-intent surgery remains an unmet need so known effective adjuvant treatments can offered to those highest recurrence. METHODS Relative gene expression level primary...
Background: The prognosis of patients with non-small cell lung cancer (NSCLC) is traditionally determined by anatomic staging using the Tumor, Node, Metastasis (TNM) system. TNM neglects biological features tumor that may be important in determining patient outcome and guiding therapeutic interventions. Identifying NSCLC at increased risk recurrence after curative-intent surgery remains an unmet need as adjuvant therapies are available reduce improve survival. Methods: Digital Display...